A Phase 4 interventional study of Insulin Glargine in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2013-08-12.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 55th largest by enrollment of the 175 interventional ones that give a count, is one of 13 that started in 2010, is one of 103 in phase 4, and was the 86th registered.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Sanofi · Sites in China
Ages 18+
Loyola University · Sites in United States
Ages 18+ · Women only
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 30–65
Yanbing Li
Ages 18–70
By country, each count listing its studies:
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 13 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 405 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 253 across the 175 interventional studies. Of the 161 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 176 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
186 studies in Diabetes Mellitus, Type 2 by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 183 finished, 46 (25%) have results posted.
Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 64th largest by enrollment of the 178 interventional ones that give a count, is one of 14 that started in 2010, is one of 75 in phase 4, and was the 97th registered.
Sanofi’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
1 of the studies testing Insulin Glargine in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 186 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To assess patient preference for Lantus SoloSTAR pen versus Lantus vial and syringe at the end of Crossover Phase (Week 4) in patients with type 2 diabetes mellitus (T2DM)
Secondary Objectives:
To compare Lantus SoloSTAR pen versus Lantus vial and syringe with regard to the following parameters:
Randomization/Crossover phase:
Re-randomization phase:
Observational phase:
All phases:
This study consisted of a 1 week Screening Phase, a 4-week Randomization/Crossover Phase, a 6-week Re-randomization Phase, followed by a 30 week Observational Phase.
The total duration of study participation was up to 41 weeks with a total treatment duration of up to 40 weeks of Lantus exposure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with a confirmed diagnosis of type 2 diabetes mellitus who were treated with any combination of 2 or 3 oral antidiabetic drugs (OADs) at a stable dose for the preceding 3 months, including but not limited to:
And for whom the Investigator/treating physician had decided that basal insulin was appropriate.
Patients who had signed an Form and Health Insurance Portability and Accountability Act (HIPAA) Authorization Form
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 mL vial, 1000 U per vial for subcutaneous administration once a day. Starting dose will be 0.2 Unit per kilogram of body weight.
Drug: Insulin Glargine
3 mL SoloSTAR pre-filled disposable insulin delivery device (pen), 300 U per device for subcutaneous administration once a day. Starting dose will be 0.2 Unit per kilogram of body weight.
Drug: Insulin Glargine
* Pharmaceutical form: solution for injection * Route of administration: subcutaneous
Also known as: Lantus
Patient Overall Preference
The patient preference was assessed in terms of the difference in scores obtained from the overall preference question 14d "Overall, what is your level of preference for each of the insulin delivery systems?" 5 points scale: from 1=Not preferred to 5= Always preferred
Time frame: At week 4 (end of crossover phase)
Patient Preference Composite Score
The patient preference composite score was the sum of the scores of the 3 following individual preference questions from the Patient preference Questionnaire: * Question 14a: How strongly do you prefer each of these insulin delivery systems to control blood sugar? * Question 14b: If using insulin for the first time, how strongly would you prefer using each of these delivery systems to overcome reluctance to use insulin? * Question 14c: How strongly would you prefer each insulin delivery system for long-term use? Each individual question scored from 1 to 5. The lowest score 1 indicated 'Not Preferred' and the highest score 5 indicated 'Always Preferred'. Therefore the total range of the composite score was 3 to 15.
Time frame: At week 4 (end of crossover phase)
Healthcare Professional's (HCP) Recommendation
The overall recommendation score was obtained from the question 20d of the Healthcare Professional Questionnaire: "Overall, how strongly would you recommend each of the insulin delivery systems for your patients?" 5 points scale: from 1= Not Recommended to 5= Recommended
Time frame: At week 4 (end of crossover phase)
Change in Fasting Plasma Glucose (FPG)
Time frame: From week 4 (baseline for re-randomization phase) to week 10 (end of re-randomization phase)
Percentage of Patients Achieving Fasting Plasma Glucose (FPG) <110 mg/dL
Time frame: At week 10 (end of re-randomization phase)
Change in Lantus Dose Injected Per Day
Time frame: From week 4 (baseline for re-randomization phase) to week 10 (end of re-randomization phase)
Percentage of Patients Achieving HbA1c Goal
Percentage of patients achieving HbA1c \< 7% at Week 40 (end of the observational phase)
Time frame: measured at week 40 or at study discontinuation
Time to First Observation of HbA1c <7%
Time frame: From week 10 to week 40 (observational phase)
Percentage of Patients Who Discontinued Investigational Product (IP) During the Crossover Phase
Time frame: From baseline to week 4 (crossover phase)
Percentage of Patients Who Discontinued Investigational Product During the Re-randomization Phase
Time frame: From week 4 to week 10 (re-randomization phase)
Percentage of Patients Who Discontinued Investigational Product During the Observational Phase
Time frame: From week 10 to week 40 (observational phase)
Number of Patients With Hypoglycemic Events
The hypoglycemic event was to be recorded on the electronic case report form hypoglycemia page and had to fit in one of the following categories: Mild-to-moderate hypoglycemia (36 mg/dL ≤ Self Monitored Blood Glucose (SMBG) \<70mg/dL), Severe hypoglycemia (assistance of another person is required, and either a recorded SMBG \<36 mg/dL, or treatment with oral carbohydrates, intravenous glucose or glucagon with prompt response) or Hypoglycemia symptoms with or without SMBG values with a documented SMBG \>70 mg/dL, or no recorded SMBG value. Only hypoglycemia events associated with coma, loss of consciousness or seizure were considered serious adverse event (SAEs).
Time frame: each study phase (crossover, re-randomization, observational) up to 40 weeks
Enrollment of patients started on October 26, 2010 and the study was completed on May 7, 2012. Patients were screened in 60 centers in the United States of America, of which 59 centers randomized patients.
| Milestone | Pen (Period 1) / Vial & Syringe (Period 2) | Vial &Syringe (Period 1) / Pen (Period 2) | SoloSTAR® Pen | Vial and Syringe |
|---|---|---|---|---|
| Started | 202 | 203 | 0 | 0 |
| Treated | 202 | 200 | 0 | 0 |
| Completed | 199 | 194 | 0 | 0 |
| Not completed | 3 | 9 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 6 | 0 | 0 |
| Milestone | Pen (Period 1) / Vial & Syringe (Period 2) | Vial &Syringe (Period 1) / Pen (Period 2) | SoloSTAR® Pen | Vial and Syringe |
|---|---|---|---|---|
| Started | 199 | 194 | 0 | 0 |
| Treated | 199 | 194 | 0 | 0 |
| Completed | 195 | 188 | 0 | 0 |
| Not completed | 4 | 6 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 4 | 5 | 0 | 0 |
| Milestone | Pen (Period 1) / Vial & Syringe (Period 2) | Vial &Syringe (Period 1) / Pen (Period 2) | SoloSTAR® Pen | Vial and Syringe |
|---|---|---|---|---|
| Started | 0 | 0 | 166 | 167 |
| Treated | 0 | 0 | 165 | 165 |
| Completed | 0 | 0 | 159 | 156 |
| Not completed | 0 | 0 | 7 | 11 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 3 |
| Withdrew: Physician decision | 0 | 0 | 3 | 2 |
| Withdrew: Completed in error | 0 | 0 | 0 | 1 |
| Milestone | Pen (Period 1) / Vial & Syringe (Period 2) | Vial &Syringe (Period 1) / Pen (Period 2) | SoloSTAR® Pen | Vial and Syringe |
|---|---|---|---|---|
| Started | 0 | 0 | 159 | 153 |
| Treated | 0 | 0 | 159 | 153 |
| Completed | 0 | 0 | 153 | 140 |
| Not completed | 0 | 0 | 6 | 13 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 7 |
| Withdrew: Physician decision | 0 | 0 | 2 | 2 |
The patient preference was assessed in terms of the difference in scores obtained from the overall preference question 14d "Overall, what is your level of preference for each of the insulin delivery systems?" 5 points scale: from 1=Not preferred to 5= Always preferred
| units on a scale | SoloSTAR® Pen | Vial and Syringe |
|---|---|---|
| Patient Overall Preference | 4.75 ± 4.75 | 2.45 (2.35 to 2.56) |
The patient preference composite score was the sum of the scores of the 3 following individual preference questions from the Patient preference Questionnaire: * Question 14a: How strongly do you prefer each of these insulin delivery systems to control blood sugar? * Question 14b: If using insulin for the first time, how strongly would you prefer using each of these delivery systems to overcome reluctance to use insulin? * Question 14c: How strongly would you prefer each insulin delivery system for long-term use? Each individual question scored from 1 to 5. The lowest score 1 indicated 'Not Preferred' and the highest score 5 indicated 'Always Preferred'. Therefore the total range of the composite score was 3 to 15.
| units on a scale | SoloSTAR® Pen | Vial and Syringe |
|---|---|---|
| Patient Preference Composite Score | 14.2 (13.88 to 14.44) | 7.49 (7.21 to 7.77) |
The overall recommendation score was obtained from the question 20d of the Healthcare Professional Questionnaire: "Overall, how strongly would you recommend each of the insulin delivery systems for your patients?" 5 points scale: from 1= Not Recommended to 5= Recommended
| units on a scale | SoloSTAR® Pen | Vial and Syringe |
|---|---|---|
| Healthcare Professional's (HCP) Recommendation | 5.0 (4 to 5) | 3.0 (1 to 5) |
| mg/dL | SoloSTAR® Pen | Vial and Syringe |
|---|---|---|
| Change in Fasting Plasma Glucose (FPG) | -14.3 ± 2.87 | -14.5 ± 2.91 |
| percentage of patients | SoloSTAR® Pen | Vial and Syringe |
|---|---|---|
| Percentage of Patients Achieving Fasting Plasma Glucose (FPG) <110 mg/dL | 28.8 | 30.5 |
| U (insulin unit) | SoloSTAR® Pen | Vial and Syringe |
|---|---|---|
| Change in Lantus Dose Injected Per Day | 6.361 ± 0.786 | 6.336 ± 0.796 |
Percentage of patients achieving HbA1c \< 7% at Week 40 (end of the observational phase)
| percentage of patients | SoloSTAR® Pen | Vial and Syringe |
|---|---|---|
| Percentage of Patients Achieving HbA1c Goal | 37.7 | 37.0 |
| Days since Re-randomization (week 4) | SoloSTAR® Pen | Vial and Syringe |
|---|---|---|
| Time to First Observation of HbA1c <7% | 166 (88 to 248) | 168 (91 to 250) |
| percentage of patients | SoloSTAR® Pen (Period 1) | Vial and Syringe (Period 2) | SoloSTAR® Pen (Period 2) | Vial and Syringe (Period 1) |
|---|---|---|---|---|
| Percentage of Patients Who Discontinued Investigational Product (IP) During the Crossover Phase | 1.49 | 2.01 | 3.09 | 3.00 |
| percentage of patients | SoloSTAR® Pen | Vial and Syringe |
|---|---|---|
| Percentage of Patients Who Discontinued Investigational Product During the Re-randomization Phase | 3.6 | 5.5 |
| percentage of patients | SoloSTAR® Pen | Vial and Syringe |
|---|---|---|
| Percentage of Patients Who Discontinued Investigational Product During the Observational Phase | 3.8 | 8.5 |
The hypoglycemic event was to be recorded on the electronic case report form hypoglycemia page and had to fit in one of the following categories: Mild-to-moderate hypoglycemia (36 mg/dL ≤ Self Monitored Blood Glucose (SMBG) \<70mg/dL), Severe hypoglycemia (assistance of another person is required, and either a recorded SMBG \<36 mg/dL, or treatment with oral carbohydrates, intravenous glucose or glucagon with prompt response) or Hypoglycemia symptoms with or without SMBG values with a documented SMBG \>70 mg/dL, or no recorded SMBG value. Only hypoglycemia events associated with coma, loss of consciousness or seizure were considered serious adverse event (SAEs).
| participants having reported the event | Crossover Phase: SoloSTAR® Pen | Crossover Phase: Vial and Syringe | Re-randomization Phase: SoloSTAR® Pen | Re-randomization Phase: Vial and Syringe | Observational Phase: SoloSTAR® Pen | Observational Phase: Vial and Syringe |
|---|---|---|---|---|---|---|
| Hypoglycemic event with or without SMBG | 72 | 83 | 43 | 48 | 76 | 73 |
| Hypoglycemia with SMBG | 69 | 81 | 38 | 47 | 75 | 71 |
| Symptomatic hypoglycemia | 57 | 68 | 37 | 37 | 61 | 61 |
| Hypoglycemia, assistance required | 3 | 2 | 2 | 5 | 8 | 11 |
| Severe hypoglycemia | 3 | 2 | 2 | 4 | 7 | 11 |
| Serious hypoglycemia | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over The median of exposure to each device was 14 days during the crossover phase. The median of exposure was 43 days in both arms during the re-randomization phase. During the observational phase, it was 209 days in the pen arm and 210 days in the vial arm.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Crossover Phase: SoloSTAR® Pen | — | 4/396 (1%) | 18/396 (4.5%) |
| Crossover Phase: Vial and Syringe | — | 1/399 (0.3%) | 5/399 (1.3%) |
| Re-randomization Phase: SoloSTAR® Pen | — | 1/165 (0.6%) | 12/165 (7.3%) |
| Re-randomization Phase: Vial and Syringe | — | 0/165 (0%) | 14/165 (8.5%) |
| Observational Phase: SoloSTAR® Pen | — | 16/159 (10.1%) | 35/159 (22%) |
| Observational Phase: Vial and Syringe | — | 14/153 (9.2%) | 34/153 (22.2%) |
| Event | Crossover Phase: SoloSTAR® Pen | Crossover Phase: Vial and Syringe | Re-randomization Phase: SoloSTAR® Pen | Re-randomization Phase: Vial and Syringe | Observational Phase: SoloSTAR® Pen | Observational Phase: Vial and Syringe |
|---|---|---|---|---|---|---|
| Non-cardiac chest painNervous system disorders | 0/396 | 0/399 | 0/165 | 0/165 | 1/159 | 2/153 |
| Atrial fibrillationCardiac disorders | 0/396 | 0/399 | 0/165 | 0/165 | 2/159 | 1/153 |
| Angina unstableCardiac disorders | 0/396 | 0/399 | 0/165 | 0/165 | 0/159 | 1/153 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/396 | 0/399 | 0/165 | 0/165 | 0/159 | 1/153 |
| Bipolar I disorderPsychiatric disorders | 0/396 | 0/399 | 0/165 | 0/165 | 0/159 | 1/153 |
| Breast calcificationsReproductive system and breast disorders | 0/396 | 0/399 | 0/165 | 0/165 | 0/159 | 1/153 |
| Cerebrovascular accidentCardiac disorders | 0/396 | 0/399 | 0/165 | 0/165 | 0/159 | 1/153 |
| Chest painCardiac disorders | 0/396 | 0/399 | 0/165 | 0/165 | 0/159 | 1/153 |
| DiarrhoeaCardiac disorders | 0/396 | 0/399 | 0/165 | 0/165 | 0/159 | 1/153 |
| Duodenal ulcer haemorrhageCardiac disorders | 0/396 | 0/399 | 0/165 | 0/165 | 0/159 | 1/153 |
| Event | Crossover Phase: SoloSTAR® Pen | Crossover Phase: Vial and Syringe | Re-randomization Phase: SoloSTAR® Pen | Re-randomization Phase: Vial and Syringe | Observational Phase: SoloSTAR® Pen | Observational Phase: Vial and Syringe |
|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 7/396 | 2/399 | 4/165 | 1/165 | 14/159 | 12/153 |
| NasopharyngitisInfections and infestations | 5/396 | 0/399 | 6/165 | 4/165 | 7/159 | 13/153 |
| SinusitisInfections and infestations | 4/396 | 1/399 | 2/165 | 6/165 | 12/159 | 6/153 |
| Oedema peripheralGeneral disorders | 2/396 | 2/399 | 0/165 | 3/165 | 8/159 | 3/153 |
Baseline characteristics provided for the population randomized for the first phase of the study: crossover phase.
| Age, Categorical(Participants) | Crossover Phase: Pen / Vial & Syringe | Crossover Phase: Vial & Syringe / Pen | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 153 | 146 | 299 |
| >=65 years | 49 | 57 | 106 |
| Age Continuous(years) | Crossover Phase: Pen / Vial & Syringe | Crossover Phase: Vial & Syringe / Pen | Total |
|---|---|---|---|
| Mean | 57.7 ± 10.1 | 58.1 ± 10.9 | 57.9 ± 10.5 |
| Sex: Female, Male(Participants) | Crossover Phase: Pen / Vial & Syringe | Crossover Phase: Vial & Syringe / Pen | Total |
|---|---|---|---|
| Female | 100 | 88 | 188 |
| Male | 102 | 115 | 217 |
| Body Weight(kg) | Crossover Phase: Pen / Vial & Syringe | Crossover Phase: Vial & Syringe / Pen | Total |
|---|---|---|---|
| Mean | 103.80 ± 26.43 | 98.48 ± 20.75 | 101.13 ± 23.87 |
| Body Mass Index(kg/m^2) | Crossover Phase: Pen / Vial & Syringe | Crossover Phase: Vial & Syringe / Pen | Total |
|---|---|---|---|
| Mean | 35.93 ± 7.87 | 33.73 ± 6.64 | 34.83 ± 7.35 |
The record gives a start of Oct 2010, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Glargine